Skip to content
Logo Mablink
Menu
  • About us
    • Our Vision
    • Leadership team
    • Investors
  • Technology
    • About ADC
    • PSARlinkTM
  • Pipeline
  • Partnering
  • Newsroom

Transforming cancer immunotherapy with next generation ADCs

Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugates (ADCs). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the design of homogenous, plasma-stable next generation ADCs with a high DAR, whilst retaining excellent pharmacological properties, in order to quickly bring new and better treatment options to cancer patients.

Our Technology Contact us

More information

  • Contact
  • Careers
  • Legal Notice (FR)
  • Privacy policy (FR)
  • Credits
Keep in touch
Copyright © 2023 Mablink Bioscience